Singaporean cell therapy biotech with off-the-shelf ambitions wraps modest IPO
Almost five months after first filing for an IPO, a small Singaporean cell therapy biotech is landing on the Nasdaq.
CytoMed Therapeutics managed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.